NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02366143,A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02366143,IMpower150,COMPLETED,"This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants were randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab).",YES,"Carcinoma, Non-Small-Cell Lung","DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|DRUG: Bevacizumab|DRUG: Carboplatin|DRUG: Paclitaxel","Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population, Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population., Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)|Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population, Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population, Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months)|Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population, Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population, Baseline until death (up approximately 53 months)","PFS, as Determined by the Independent Review Facility (IRF) in Arm B Versus Arm C in Teff-High-WT Population and ITT-WT Population, PFS, as determined by the independent review facility (IRF) Using RECIST v1.1 in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population., Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)|PFS, as Determined by the Investigator in Arm B Versus Arm C in Teff High Population and ITT Population, PFS, as determined by the investigator according to RECIST v1.1, in Arm B versus C in the Teff high population and ITT population., Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)|PFS, as Determined by the Investigator in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population, PFS, as determined by the investigator according to RECIST v1.1, in Arm A versus B in the Teff high-WT population and ITT-WT population., Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)|PFS, as Determined by the Investigator in Arm B Versus Arm C by PD-L1 Subgroup, PFS as Determined by the Investigator according to RECIST v1.1, in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population), Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)|OS in Arm B Versus Arm C by PD-L1 Subgroup, OS in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population), Baseline until death (up to approximately 34 months)|OS in Arm A Versus Arm C by PD-L1 Subgroup, OS in Arm A Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population), Baseline until death (up approximately 53 months)|OS in Arm B Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population, Baseline until death (up to approximately 34 months)|OS in Arm A Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population, Baseline until death (up approximately 53 months)|OS in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population, Baseline until death (up approximately 53 months)|Duration of Response (DOR), as Determined By Investigator in Arm B Versus Arm C, DOR, as determined by investigator according to RECIST v1.1 in Arm B versus Arm C in the Teff high-WT population and the ITT-WT population., Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)|Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator in the Teff-High-WT Population and ITT-WT Population, Percentage of Participants With an Objective Response (OR) (Complete Response \[CR\] or Partial Response \[PR\]) as Determined by the Investigator using RECIST v1.1 in the Teff-High-WT population and ITT-WT population., Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)|OS Rates at Years 1 and 2 in Arm B Versus Arm C, OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population., Baseline to 2 years or death, whichever occurs first.|OS Rates at Years 1 and 2 in Arm A Versus Arm C, OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population., Baseline to 2 years or death, whichever occurs first.|Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms Determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score, EORTC QLQ-C30 is a validated \& reliable self-report measure (Aaronson et al.1993;Fitzsimmons et al.1999) that consists of 30 questions that assess 5 aspects of patient functioning (physical,emotional,role, cognitive,and social), 3 symptom scales (fatigue,nausea \& vomiting, pain),global health/quality of life,and six single items (dyspnea,insomnia, appetite loss,constipation,diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life);however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al.1998)., Baseline up to approximately 29 months|TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score, QLQ-LC13 Quality-of-Life Questionnaire Lung Cancer Module incorporates one multiple-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998)., Baseline up to approximately 29 months|Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale, The SILC (Symptoms in Lung Cancer) scale was used to assess patient-reported severity of lung cancer symptoms (chest pain, dyspnea, and cough). The SILC scale is a 9-item content validated self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a symptom severity score. The SILC questionnaire comprises three individual symptoms (dyspnea, cough, chest pain) and are scored at the individual symptom level, thus have a dyspnea score, chest pain score, and cough score. Each individual symptom score is calculated as the average of responses for the symptom items \[e.g. Chest Pain Score=mean (item 1; item 2)\]. An increase in score is suggestive of a worsening in symptomology (i.e. frequency or severity). A score change of ≥0.3 points for the dyspnea and cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for the chest pain score is considered to be clinically significant., Baseline up to approximately 29 months|Percentage of Participants With Adverse Events, Percentage of participants with at least one adverse event., Baseline up to data cutoff date 7 December 2020 (up to approximately 68 months)|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab, Baseline up to approximately 29 months|Maximum Observed Serum Concentration (Cmax) of Atezolizumab in Arm A and Arm B, The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes., Day 1 of Cycle 1 and 3 (Cycle length=21 days)|Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Arm A and Arm B, Day 21 of Cycles 1, 2 3, and 7 (Cycle length=21 days)|Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C, Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 h after carboplatin infusion (infusion duration=15 to 30 minutes) on D1 of Cy1,3 (Cycle length=21 days)|Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C, Predose (same day of treatment administration), 5-10 minutes before end of paclitaxel infusion, 1 h after paclitaxel infusion (infusion duration=3 h) on D1 of Cy1,3 (Cycle length=21 days)|Cmax of Bevacizumab in Arm B and Arm C, Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length=21 days)|Cmin of Bevacizumab in Arm B and Arm C, Cycle 1 Day 1 and Cycle 2 Day 21 (Cycle length=21 days)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1202,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GO29436|2014-003207-30,2015-03-31,2019-09-13,2020-12-07,2015-02-19,2020-10-27,2021-09-23,"Ironwood Cancer & Research Centers, Chandler, Arizona, 85224, United States|Arizona Oncology Associates, Flagstaff, Arizona, 86001, United States|Southern CA Permanente Med Grp, Bellflower, California, United States|Marin Cancer Care Inc, Greenbrae, California, 94904, United States|Scripps Health, La Jolla, California, 92037, United States|Chao Family Comprehensive Cancer Center UCI, Orange, California, 92868, United States|Rocky Mountain Cancer Center, Denver, Colorado, 80218, United States|Kaiser Permanente, Lonetree, Colorado, 80124, United States|Danbury Hospital, Danbury, Connecticut, 06810, United States|Yale Cancer Center, New Haven, Connecticut, 06520, United States|Holy Cross Hospital Inc, Fort Lauderdale, Florida, 33308, United States|Cancer Specialists of North Florida - Baptist South, Jacksonville, Florida, 32258, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, 34952, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, 30318, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Univ of Chicago, Chicago, Illinois, 60637, United States|Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States|Oncology Specialists, S.C., Park Ridge, Illinois, 60068, United States|Hematology-Oncology; Associates of the Quad Cities, Bettendorf, Iowa, 52722, United States|Norton Cancer Institute, Louisville, Kentucky, 40202, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|Mercy Medical Center, Baltimore, Maryland, 21202, United States|Regional Cancer Care Associates, Bethesda, Maryland, 20817, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, 21044, United States|St. Joseph Mercy Health System, Ann Arbor, Michigan, 48106, United States|St. Luke's Regional Cancer Center, Duluth, Minnesota, 55805, United States|Park Nicolett - Frauenshuh Cancer Center, Saint Louis Park, Minnesota, 55426, United States|St. Luke's Cancer Institute, Kansas City, Missouri, 64111, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, 63131, United States|Billings Clinic, Billings, Montana, 59102, United States|Montana Cancer Specialists, Missoula, Montana, 59802, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, 89014, United States|Summit Medical Group, Berkeley Heights, New Jersey, 07922, United States|Valley Hospital; Oncology Research, Paramus, New Jersey, 07652, United States|Regional Cancer Care Associates LLC, Sewell, New Jersey, 08080, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|Maimonides Medical Center, Brooklyn, New York, 11219, United States|First Health of the Carolinas, Pinehurst, North Carolina, 28374, United States|University of Cincinnati, Cincinnati, Ohio, 45203-0542, United States|Mercy St Anne Hospital, Toledo, Ohio, 43623, United States|Bend Memorial Clinic, Bend, Oregon, 97701, United States|St. Charles Medical Center Bend; Cancer Care Of The Cascades, Bend, Oregon, 97701, United States|Willamette Valley Cancer Insitute and Research Center, Springfield, Oregon, 97477, United States|St. Luke's Cancer Care Associates, Bethlehem, Pennsylvania, 18015, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, 15212, United States|Univ of Pittsburgh Medical Ctr, Pittsburgh, Pennsylvania, 15232, United States|West Clinic, Germantown, Tennessee, 38138, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, 37920, United States|Houston Methodist Cancer Center, Houston, Texas, 77030, United States|Longview Cancer Center, Longview, Texas, 75601, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Virginia Cancer Institute, Richmond, Virginia, 23226, United States|Blue Ridge Cancer Care, Roanoke, Virginia, 24014, United States|MultiCare Regional Cancer Center - Auburn, Auburn, Washington, 98002-4117, United States|Providence Regional Cancer Partnership, Everett, Washington, 98201, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|Medical Oncology Associates, Spokane, Washington, 99208, United States|West Virginia University; Mary Babb Randolph Can Ctr, Morgantown, West Virginia, 26506, United States|Centro Medico Austral, Buenos Aires, 1019, Argentina|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, C1125ABD, Argentina|Sanatorio Allende, Cordoba, X5000JHQ, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, F5300COE, Argentina|Hospital Provincial del Centenario, Rosario, 2000, Argentina|Fundacion Koriza, Santa Rosa, 6300, Argentina|Centro de Investigacion; Clinica - Clinica Viedma S.A., Viedma, R8500ACE, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Nepean Cancer Care Centre, Sydney, New South Wales, 2747, Australia|Prince Charles Hospital; Department of Medical Oncology, Chermside, Queensland, 4032, Australia|Townsville Hospital, Townsville, Queensland, 4810, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, 5037, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Launceston General Hospital, Launceston, Tasmania, 7250, Australia|Frankston Hospital, Frankston, Victoria, 3199, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Cabrini Hospital Malvern, Malvern, Victoria, 3144, Australia|The Alfred Hospital, Prahan, Victoria, 3181, Australia|Sunshine Hospital, St Albans, Victoria, 3021, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Paracelsus Medizinische Privatuniversität, Salzburg, 5020, Austria|Klinikum Wels-Grieskirchen, Wels, 4600, Austria|CHU de Liège, Liège, 4000, Belgium|Clinique Ste-Elisabeth, Namur, 5000, Belgium|CETUS Hospital Dia Oncologia, Uberaba, MG, 38082-049, Brazil|Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica, Londrina, PR, 86 015 520, Brazil|Liga Norte Riograndense Contra O Câncer, Natal, RN, 59040150, Brazil|IPCEM; Instituto de Pesquisa de Estudos Multicêntricos, Caxias do Sul, RS, 95070-560, Brazil|Hospital Mae de Deus, Porto Alegre, RS, 90470-340, Brazil|Hospital de Cancer de Barretos, Barretos, SP, 14784-400, Brazil|Instituto Ribeirãopretano de Combate Ao Câncer; Centro Especializado De Oncologia, Ribeirão Preto, SP, 14015-130, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, 15090-000, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, 01509-010, Brazil|Multiprofile Hospital for Active Treatment Central Onco Hospital OOD, Plovdiv, 4000, Bulgaria|MHAT Serdika, EOOD, Sofia, 1303, Bulgaria|Lakeridge Health Center, Oshawa, Ontario, L1J 2J2, Canada|Clinica Santa Maria, Santiago, 0, Chile|Health & Care SPA, Santiago, 7500006, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, 4810469, Chile|Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, 33076, France|CHU de Grenoble, Grenoble, 38043, France|Centre Jean Bernard Clinique Victor Hugo, Le Mans, 72015, France|Hôpital Saint Joseph, Marseille, 13008, France|Hopital Nord AP-HM, Marseille, 13015, France|Hôpital Européen Georges Pompidou, Paris, 75908, France|CHU de Bordeaux, Pessac, 33600, France|Service de Pneumologie Centre Hospitalier Régional La Réunion Site Felix Guyon, Saint Denis Cedex, 97405, France|CH de Saint Quentin, Saint Quentin, 2100, France|Centre Hospitalier Intercommunal Toulon - La Seyne sur Mer, Toulon, 83000, France|Hôpital d'Instruction des Armées de Sainte Anne; Service de Pneumologie, Toulon, 83000, France|Hôpital Larrey;Université Paul Sabatier, Toulouse, 31059, France|Zentralklinikum Augsburg, Augsburg, 86156, Germany|Helios Klinikum Emil von Behring GmbH, Berlin, 14165, Germany|Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie, Bielefeld, 33611, Germany|Augusta Kranken-Anstalt gGmbH, Bochum, 44791, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, 01307, Germany|St. Elisabethen Krankenhaus, Frankfurt am Main, 60487, Germany|LungenClinic Großhansdorf GmbH, Großhansdorf, 22927, Germany|Krankenhaus Martha-Maria; Halle-Dolau gGmbH, Halle, 06120, Germany|Asklepios Klinik Harburg, Hamburg, 21075, Germany|Lungenklinik Hemer, Hemer, 58675, Germany|Universität Des Saarlandes; Klinik für Innere Medizin V, Homburg, 66421, Germany|Kliniken der Stadt Koln gGmbH; Lungenklinik Onkologische Ambulanz, Koln, 51109, Germany|Klinik Loewenstein gGmbH; Onk & Pal, Loewenstein, 74245, Germany|Klinikum Bogenhausen, München, 81925, Germany|Krankenhaus Barmherzige Bruder Regensburg, Regensburg, 93049, Germany|Klinikum der Universität Regensburg, Regensburg, 93053, Germany|Stiftung Mathias-Spital Rheine, Rheine, 48431, Germany|AORN A Cardarelli, Napoli, Campania, 80131, Italy|Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica, Roma, Lazio, 00128, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, 00152, Italy|Università Cattolica Del S Cuore, Roma, Lazio, 00168, Italy|Istituto Nazionale per la Ricerca sul Cancro di Genova, Genova, Liguria, 16132, Italy|ASL 3 Genovese; DSM, Genova, Liguria, 16147, Italy|A.O.U. Maggiore della Carità, Novara, Piemonte, 28100, Italy|Azienda Unita Sanitaria Locale N1 Sassari; Unita Operativa Di Oncologia Medica, Sassari, Sardegna, 07100, Italy|Policlinico Vittorio Emanuele, Catania, Sicilia, 95123, Italy|Ospedale Versilia, Lido Di Camaiore, Toscana, 55043, Italy|Ospedale Civile - Livorno, Livorno, Toscana, 57124, Italy|National Hospital Organization Shikoku Cancer Center, Ehime, 791-0280, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, 810-8563, Japan|NHO Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Kurume University Hospital, Fukuoka, 830-0011, Japan|Kanagawa Cardiovascular and Respiratory Center, Kanagawa, 236-0051, Japan|Kitasato University Hospital, Kanagawa, 252-0375, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|Miyagi Cancer Center, Miyagi, 981-1293, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Osaka City University Hospital, Osaka, 545-8586, Japan|National Hospital Organization Osaka Toneyama Medical Center, Osaka, 560-8552, Japan|Toranomon Hospital, Tokyo, 105-8470, Japan|Center Hospital of the National Center for Global Health and Medicine, Tokyo, 162-0052, Japan|Kyorin University Hospital, Tokyo, 181-8611, Japan|Wakayama Medical University Hospital, Wakayama, 641-8510, Japan|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, LV-1079, Latvia|Pauls Stradins Clinical University Hospital, Rīga, LV-1002, Latvia|National Cancer Institute, Vilnius, 08660, Lithuania|Centro Universitario Contra El Cancer, Monterrey, 64020, Mexico|Cancerologia de Queretaro, Queretaro, 76090, Mexico|Centro Hemato Oncologico Privado; Oncologia, Toluca, 50080, Mexico|Jeroen Bosch Ziekenhuis, 'S Hertogenbosch, 5223 GZ, Netherlands|Amsterdam UMC Location VUMC, Amsterdam, 1081 HV, Netherlands|Amphia Ziekenhuis; Afdeling Longziekten, Breda, 4818 CK, Netherlands|Ziekenhuis Gelderse Vallei, EDE, 6716 RP, Netherlands|Tergooiziekenhuizen, Hilversum, 1201 DA, Netherlands|Spaarne Gasthuis; Spaarne Ziekenhuis, Hoofddorp, 2134 TM, Netherlands|Maastricht University Medical Center, Maastricht, 6229 HX, Netherlands|St. Antonius Ziekenhuis; R&D Long, Nieuwegein, 3435 CM, Netherlands|Erasmus MC; Afdeling Longziekten, Rotterdam, 3015 GD, Netherlands|Maasstad ziekenhuis, Rotterdam, 3079 DZ, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, 3584 CX, Netherlands|Gelre Ziekenhuizen, Zutphen, Zutphen, 7207 AE, Netherlands|Centro Medico Monte Carmelo, Arequipa, 04001, Peru|Centro Especializado de Enfermedades Neoplásicas, Arequipa, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Lima 34, Peru|Centro Hospitalar E Universitário de Coimbra EPE, Coimbra, 3000-602, Portugal|Instituto Portugues Oncologia de Lisboa Francisco Gentil EPE, Lisboa, 1099-023, Portugal|Hospital Pulido Valente; Servico de Pneumologia, Lisboa, 1796-001, Portugal|Centro Hospitalar do Porto - Hospital de Santo António, Porto, 4099-001, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, 4200-072, Portugal|Hospital de Sao Joao; Servico de Pneumologia, Porto, 4200, Portugal|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, 143423, Russian Federation|Russian Oncology Research Center n.a. N.N. Blokhin, Moscow, 115478, Russian Federation|Clinical Oncology Dispensary, Omsk, 644013, Russian Federation|Evromedservis LCC, Pushkin, 196603, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, 197022, Russian Federation|National Cancer Centre; Medical Oncology, Singapore, 169610, Singapore|Univerzitna nemocnica Bratislava, Bratislava, 813 69, Slovakia|Narodny onkologicky ustav, Bratislava, 833 10, Slovakia|POKO Poprad s.r.o., Poprad, 058 01, Slovakia|Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia, L'Hospitalet de Llobregat, Barcelona, 08908, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, 8208, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, 07014, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, LAS Palmas, 35016, Spain|Complejo Hospitalario U. de Ourense, Ourense, Orense, 32005, Spain|Hospital Lluis Alcanyis De Xativa, Xativa, Valencia, 46800, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario Reina Sofia, Cordoba, 14004, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, 27003, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, 28007, Spain|Hospital Universitario La Paz, Madrid, 280146, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, 28034, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, 28040, Spain|Hospital Universitario Fundación Jimenez Díaz, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, 28050, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Kantonsspital Baselland, Bruderholz, 4101, Switzerland|Luzerner Kantonsspital Sursee, Luzern, 6000, Switzerland|Kantonsspital St. Gallen; Onkologie/Hämatologie, St. Gallen, 9007, Switzerland|Changhua Christian Hospital; Hematology-Oncology, Changhua, 500, Taiwan|Kaohsiung Medical University Hospital; Department of Urology, Kaohsiung City, 807, Taiwan|Chi Mei Medical Center Liou Ying Campus, Liuying Township, 736, Taiwan|Chang Gung Memorial Hospital Chiayi, Putzu, 613, Taiwan|National Cheng Kung Univ Hosp, Tainan, 00704, Taiwan|National Taiwan Uni Hospital, Taipei City, 10041, Taiwan|Cheng Hsin General Hospital, Taipei, 112, Taiwan|Tri-Service General Hospital, Taipei, 11490, Taiwan|Chang Gung Medical Foundation Linkou Branch, Taoyuan City, 333, Taiwan|Taichung Veterans General Hospital, Xitun Dist., 40705, Taiwan|ME Bukovinian Clinical Oncology Center, Chernivtsi, Chernihiv Governorate, 58013, Ukraine|Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy, Dnipropetrovsk, Katerynoslav Governorate, 49102, Ukraine|Uzhgorod Central City Clinical Hospital, Uzhhorod, Katerynoslav Governorate, 88000, Ukraine|MNPE Zaporizhzhia Regional Antitumor Center ZRC, Zaporizhzhia, Katerynoslav Governorate, 69040, Ukraine|Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs, Kharkiv, Kharkiv Governorate, 61070, Ukraine|MNPE Transcarpathian Antitumor Center of the Transcarpathian Regional Council; Chemotherapy Dept, Uzhhorod, Kherson Governorate, 88014, Ukraine|Municipal Institution SubCarpathian Clinical Oncological Centre; Surgical department#2, Ivano-Frankivsk, KIEV Governorate, 76018, Ukraine|Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council, Vinnytsia, KIEV Governorate, 21029, Ukraine|SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine, Kharkiv, 61024, Ukraine|ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department, Kryvyi Rih, 50048, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, 03115, Ukraine|Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department, Poltava, 36011, Ukraine|Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, Sumy, 40005, Ukraine","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/43/NCT02366143/Prot_001.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/43/NCT02366143/SAP_000.pdf"
